|
May 14
|
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
|
|
May 8
|
Pliant Therapeutics First Quarter 2024 Earnings: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)
|
|
May 7
|
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
|
|
May 6
|
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
|
|
Apr 2
|
Pliant Therapeutics to Participate in Upcoming Investor Events
|
|
Mar 27
|
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
|
|
Mar 12
|
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
|
|
Mar 7
|
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline
|